Vycor Adds Two Patents for Its New Spinal ViewSite(TM) Cervical Access System
April 25 2013 - 7:30AM
Marketwired
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today it has
secured two new patents (2008-518369 and 11/993280) covering its
Spinal ViewSite™ Cervical Access System (VCAS). The addition of
these patents brings Vycor's total patent portfolio to 34 issued
and 21 pending. The Company's Vycor Medical division now has 5
issued patents and 11 patents pending, and its NovaVision unit now
has 29 issued patents and 10 patents pending.
Vycor's VCAS is designed to facilitate anterior cervical
procedures of the spine, and deliver clinical and cost benefits to
a sizeable global market. A surgeon would use the VCAS technology
to access the anterior cervical surgical site (the uppermost
vertebrae located in the neck). This type of surgery typically
involves disk removal or replacement procedures located near very
critical and delicate structures, such as the larynx, esophagus and
carotid artery. Vycor's VBAS and VCAS have FDA 510(k) clearance in
the U.S.
The two patents granted for VCAS were for the U.S. and Japan and
cover an introducer and retractor system for use in spinal
surgeries. Devices covered by the claims provide improved access
and visualization into the surgical workspace, and allow the
surgeon to selectively expand or contract the size of the work
space formed by the retractor after the retractor is in place.
There are a number of additional patents for VCAS still being
pursued in various geographies.
Commercialization of VCAS is conditional upon successful
prototype modifications and subsequent field-testing, which may
require recertification (depending on the magnitude of design
changes). Eventually, Vycor could expand its spine product
portfolio to encompass a much wider range of procedures,
conditional upon the success of the initial VCAS models.
"We continue to view development of patented and proprietary new
products as being key to Vycor's product suite becoming the
Standard of Care for neurosurgical retraction and patent
protection. We are working hard on building a new product pipeline
which will complement our existing VBAS product line," stated David
Cantor, Vycor's President.
About Vycor Medical, Inc. With corporate
headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a
publicly traded company (OTCBB: VYCO) dedicated to providing the
medical community with innovative and superior surgical and
therapeutic solutions and has a growing portfolio of FDA-approved
medical solutions that are changing and improving lives every day.
The Company operates two business units: Vycor Medical and
NovaVision, both of which adopt a minimally or non-invasive
approach. Both technologies have exceptional sales growth
potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating revenue.
The Company has a strong patent portfolio with 34 granted patents
and a further 21 patents pending.
Vycor Medical's flagship, ViewSite™ Surgical Access Systems
(VBAS) is a suite of clear cylindrical minimally invasive
disposable devices that hold the potential for speedier, safer and
more economical brain surgeries and a quicker patient discharge.
VBAS is designed to optimize neurosurgical site access, reduce
patient risk, accelerate recovery and add tangible value to the
professional medical community. Vycor Medical is ISO 13485:2003
compliant, has FDA 510(K) clearance for VBAS for brain and spine
surgeries and regulatory approvals for brain surgeries in
Australia, Canada, China, Europe, Japan, Korea and Russia. For an
overview of Vycor Medical's VBAS see
http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation
therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision
impairments. The company's proprietary Visual Restoration Therapy®
(VRT) platform is clinically supported to improve lost vision
resulting from stroke, traumatic brain injury ("TBI"), or other
acquired brain injuries. VRT is the only FDA 510K cleared medical
device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any
ophthalmologist, optometrist, neurologist or physiatrist. VRT also
has CE Marking for the EU. NovaVision also provides Neuro-Eye
Therapy (NeET) in the EU, aimed at increasing visual sensitivity
deep within the field defect. NovaVision also provides a fully
portable and ADA-compliant Head Mounted Perimeter (HMP™) which aids
in the detection and measurement of visual field deficits. For an
overview of NovaVision see
http://player.vimeo.com/video/39765566
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The words "forecast,"
"anticipate," "estimate," "project," "intend," "expect," "should,"
"believe," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve, and are subject to known and unknown risks, uncertainties
and other factors which could cause Vycor Medical's actual results,
performance (financial or operating) or achievements to differ from
the future results, performance (financial or operating) or
achievements expressed or implied by such forward-looking
statements. The risks, uncertainties and other factors are more
fully discussed in Vycor Medical's filings with the U.S. Securities
and Exchange Commission. All forward-looking statements
attributable to Vycor Medical herein are expressly qualified in
their entirety by the above-mentioned cautionary statement. Vycor
Medical disclaims any obligation to update forward-looking
statements contained in this estimate, except as may be required by
law.
Vycor Medical, Inc. Investor Contacts: The Del Mar
Consulting Group, Inc. Robert B. Prag President 858-794-9500 Email
Contact or Alex Partners, LLC Scott Wilfong President 425- 242-0891
Email Contact
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jul 2023 to Jul 2024